Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize therapeutics for unmet medical needs and has demonstrated potential for growth with a strong pipeline of products. The positive results from the company's studies and strong management outlook for their products, as well as the potential for future partnerships and acquisitions, make Alkermes a promising investment opportunity with a potential to generate strong returns for investors in the long term.

Bears say

Alkermes is facing challenges in adequately defining the patient population for its narcolepsy treatment and may face limitations on the initial label. The company's upcoming Phase 2 ADHD trial, while promising, will not have results available for several years and may face competition from both non-stimulant and stimulant treatments. Safety concerns, such as poliuria and insomnia, may also pose risks to the success of Alkermes's products.

Alkermes (ALKS) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 15 analysts, Alkermes (ALKS) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.